Efficacy News and Research

RSS
Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Research roundup: Hospital readmissions; researchers mistrust social media; premiums in Washington state

Research roundup: Hospital readmissions; researchers mistrust social media; premiums in Washington state

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

Researchers develop rapid-acting antidepressants for treatment-resistant depression

Researchers develop rapid-acting antidepressants for treatment-resistant depression

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

Infliximab biosimilar CT-P13 improves disease activity in patients with Ankylosing Spondylitis

Heart rate may identify premature infants at risk of developing necrotizing enterocolitis

Heart rate may identify premature infants at risk of developing necrotizing enterocolitis

2 medications equally effective in treating major epileptic brain seizures in children

2 medications equally effective in treating major epileptic brain seizures in children

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Exercise transiently suppresses inflammation in rheumatic disease

Exercise transiently suppresses inflammation in rheumatic disease

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

BioLineRx gets Notice of Allowance for patent related to new treatment for celiac disease

ClarityMD effective in clearing acne without irritation

ClarityMD effective in clearing acne without irritation

FDA grants orphan drug designation to EffRx Pharmaceuticals' EX404 for treatment of PCOS

FDA grants orphan drug designation to EffRx Pharmaceuticals' EX404 for treatment of PCOS

Treato releases third version of flagship patient intelligence platform

Treato releases third version of flagship patient intelligence platform

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

electroCore's non-invasive vagus nerve stimulation therapy reduces cluster headache attacks

electroCore's non-invasive vagus nerve stimulation therapy reduces cluster headache attacks

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.